KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) announced today it has received allowance of its patent application protecting its flagship product, ProvectaTM, from the European Patent Office (EPO). This allowance follows several successful U.S. filings for patent protection and is the second international case covering the intellectual property of Provecta. In December 2006, the Company announced similar allowance by the Intellectual Property Office of Taiwan (TIPO).
